Table 3.
Treatment modalities in non-diabetic and diabetic patients with chronic pancreatitis
| No diabetes (n=788) | Diagnosed with diabetes (n=383) | ||||
|---|---|---|---|---|---|
| N | % | N | % | P-value | |
| Pain medicationsa | |||||
| Continuous opioids | 161 | 39.8% | 85 | 34.8% | 0.24 |
| Intermittent opioids | 103 | 25.4% | 57 | 23.4% | 0.5739 |
| Non-opioids only | 28 | 6.9% | 22 | 9.0% | 0.2145 |
| No pain medications | 113 | 27.9% | 80 | 32.8% | 0.3629 |
| On pancreatic enzymes | 515 | 65.4% | 267 | 69.7% | 0.1461 |
| Antioxidants or vitamins | 151 | 19.2% | 86 | 22.5% | 0.0051 |
| Celiac plexus block | 46 | 5.8% | 16 | 4.2% | 0.2672 |
| Endoscopy performed | 0.1967 | ||||
| No ERCP | 382 | 48.5% | 202 | 52.7% | |
| Other ERCP | 98 | 12.4% | 52 | 13.6% | |
| Pancreatic ERCP | 308 | 39.1% | 129 | 33.7% | |
| ERCP therapies | 406 | 51.5% | 181 | 30.8% | 0.1908 |
| Biliary stent | 88 | 11.2% | 52 | 13.6% | 0.2496 |
| Pancreatic duct stent | 269 | 34.1% | 98 | 25.6% | 0.0031 |
| Pancreatic stone removal | 95 | 12.1% | 54 | 14.1% | 0.3501 |
| Biliary or pancreatic | 321 | 40.7% | 141 | 36.8% | 0.203 |
| Sphincterotomy | |||||
| Surgery performed | 133 | 16.9% | 103 | 26.9% | <0.0001 |
| Resection procedure | 64 | 8.1% | 66 | 17.2% | <0.0001 |
| Drainage procedure | 49 | 6.2% | 38 | 9.9% | 0.0319 |
| Operation for cyst/pseudocyst | 37 | 4.7% | 32 | 8.4% | 0.0167 |
ERCP, endoscopic retrograde cholangiopancreatography; NAPS2-AS, North American Pancreatitis study 2 Ancillary study; NAPS2-CV, North American Pancreatitis study 2 continuation and validation study.
a
Information on pain experience and pain medication use per physician report is shown from the NAPS2-CV and NAPS2-AS studies only—relevant sample sizes were—diabetics (n =244) and non-diabetics (n =405).